振德醫療(603301.SH)實控人沈振芳質押480萬股
格隆匯11月15日丨振德醫療(603301.SH)公佈,公司實際控制人沈振芳持有公司股份665萬股,佔公司總股本4.75%,本次完成480萬股質押後,沈振芳質押股份數量為480萬股,佔其持股總數的72.18%,佔公司總股本3.43%。
公司控股股東浙江振德控股有限公司及其一致行動人(魯建國、沈振芳)合計持有公司股份8464.40萬股,佔本公司總股本60.46%,累計質押數量(含本次)為480萬股,佔其持股總數的5.67%,佔公司總股本的3.43%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.